

Neuromuscular disorder

ALS/MND

1. Miao X, Wu X, Shi W. Umbilical cord mesenchymal stem cells in neurological disorders: a clinical study. <https://www.ncbi.nlm.nih.gov/pubmed/26118125>
2. Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, Mehra M, Aricha R, Gothelf Y, Brown RH. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. *Neurology.* 2019 Dec 10;93(24):e2294-e2305. doi: 10.1212/WNL.00000000000008620. Epub 2019 Nov 18. PmID: 31740545; PMCID: PMC6937497.
3. Cudkowicz ME, Lindborg SR, Goyal NA, miller RG, Burford MJ, Berry JD, Nicholson KA, Mozaffar T, Katz JS, Jenkins LJ, Baloh RH, Lewis RA, Staff NP, Owegi MA, Berry DA, Gothelf Y, Levy YS, Aricha R, Kern RZ, Windebank AJ, Brown RH Jr. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. *Muscle Nerve.* 2022 Mar;65(3):291-302. doi: 10.1002/mus.27472. Epub 2022 Jan 5. PmID: 34890069; PMCID: PMC9305113.
4. Mazzini L, Ferrari D, Andjus PR, et al. Advances in stem cell therapy for amyotrophic lateral sclerosis. *Expert Opin Biol Ther.* 2018;18(8):865-881. doi:10.1080/14712598.2018.1503248 <https://www.ncbi.nlm.nih.gov/pubmed/30025485>
5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780495/> Moura MC, Novaes MR, Zago YS, Eduardo EJ, Casulari LA. Efficacy of Stem Cell Therapy in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *J Clin Med Res.* 2016;8(4):317–324. doi:10.14740/jocmr2495w
6. Abdul Wahid SF, Law ZK, Ismail NA, Azman Ali R, Lai NM. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. *Cochrane Database Syst Rev.* 2016;11:CD011742. <https://www.ncbi.nlm.nih.gov/pubmed/27822919> doi:10.1002/14651858.CD011742.pub2
7. Aljabri A, Halawani A, Bin Lajdam G, Labban S, Alshehri S, Felemban R. The Safety and Efficacy of Stem Cell Therapy as an Emerging Therapy for ALS: A Systematic Review of Controlled Clinical Trials. *Front Neurol.* 2021 Dec 1;12:783122. doi: 10.3389/fneur.2021.783122. PmID: 34938264; PMCID: PMC8685950.

8. Sharma AK, Sane HM, Paranjape AA, Gokulchandran N, Nagrajan A, D'sa M, et al. The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study. *Am J Stem Cells.* 2015;4(1):50–65. <https://www.ncbi.nlm.nih.gov/pubmed/25973331>
9. Sharma A, Sane H, Paranjape A, Varghese R, Biju H, Nair V, Sawant D, Gokulchandran N, Badhe P. Role of reproductive hormonal status on the outcome of Autologous bone marrow mononuclear cells intrathecal Transplantation combined with standard treatments in patients With amyotrophic lateral sclerosis - a controlled cohort study. *Neurology.* 2021 Jul; 10(7): 8-13.
10. Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, Siwek T, Grudniak M. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. *Stem Cell Rev Rep.* 2020 Oct;16(5):922-932. doi: 10.1007/s12015-020-10016-7. PMID: 32725316; PMCID: PMC7456414.
11. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD. Intradiscal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. *Annals of Neurology* [Internet]. 2014 Mar [cited 2022 Sep 22];75(3):363-73. Available from: <https://doi.org/10.1002/ana.24113>
12. Morata-Tarifa C, Azkona G, Glass J, Mazzini L, Sanchez-Pernaute R. Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. *npj Regenerative Medicine* [Internet]. 2021 Apr 1 [cited 2022 Sep 22];6(1). Available from: <https://doi.org/10.1038/s41536-021-00131-5>
13. "Chen L, Huang H, Zhang J, Zhang F, Liu Y, Xi H, Wang H, Gu Z, Song Y, Li Y, Tan K. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.* 2007 Sep;21(9):961-6. PubMed PMID: 17933231.
14. Letizia Mazzini, Franca Fagioli, Riccardo Boccaletti, Katia Mareschi, Giuseppe Oliveri, Carlo Olivieri, Ilaria Pastore, Roberto Marasso& Enrico Madon (2003) Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans, *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, 4:3, 158-161, DOI: 10.1080/14660820310014653
15. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.

- Cytotherapy. 2009;11(1):26-34. doi:10.1080/14653240802644651
<https://www.ncbi.nlm.nih.gov/pubmed/19191058>
16. Deda H, Inci MC, Kürekçi AE, Sav A, Kayihan K, Ozgün E, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11(1):18–25. <https://www.ncbi.nlm.nih.gov/pubmed/19012065>
17. Gamez J, Carmona F, Raguer N, Ferrer-Sancho J, Martín-Henao GA, Martí-Beltrán S, et al. Cellular transplants in amyotrophic lateral sclerosis patients: an observational study. Cytotherapy. 2010 Sep;12(5):669–77. <https://www.ncbi.nlm.nih.gov/pubmed/20586670>
18. Prabhakar S, Marwaha N, Lal V, Sharma RR, Rajan R, Khandelwal N. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurol India. 2012 Oct;60(5):465–9. <https://www.ncbi.nlm.nih.gov/pubmed/23135021>
19. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Arch Neurol. 2010 Oct;67(10):1187–94. <https://www.ncbi.nlm.nih.gov/pubmed/20937945>
20. Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016 Mar;73(3):337–44. <https://www.ncbi.nlm.nih.gov/pubmed/26751635>
21. Riley J, Glass J, Feldman EL, Polak M, Bordeau J, Federici T, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery. 2014 Jan;74(1):77–87. <https://www.ncbi.nlm.nih.gov/pubmed/24018694>
22. Mazzini L, Mareschi K, Ferrero I, miglioretti M, Stecco A, Servo S, et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy. 2012 Jan;14(1):56–60. <https://www.ncbi.nlm.nih.gov/pubmed/21954839>
23. Blanquer M, Moraleda JM, Iniesta F, Gómez-Espuch J, Meca-Lallana J, Villaverde R, et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells Dayt Ohio. 2012 Jun;30(6):1277–85. <https://www.ncbi.nlm.nih.gov/pubmed/22415951>

24. Oh K-W, Moon C, Kim HY, Oh S-I, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. *Stem Cells Transl Med.* 2015 Jun;4(6):590–7 <https://www.ncbi.nlm.nih.gov/pubmed/25934946>
25. Huang H, Chen L, Xi H, Wang H, Zhang J, Zhang F, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. *Clin Transplant.* 2008 Dec;22(6):710–8. <https://www.ncbi.nlm.nih.gov/pubmed/18673377>
26. Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. *Stem Cells Dayt Ohio.* 2012 Jun;30(6):1144–51. <https://www.ncbi.nlm.nih.gov/pubmed/22415942>
27. Rushkevich YN, Kosmacheva SM, Zabrodets GV, Ignatenko SI, Goncharova NV, Severin IN, et al. The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus. *Bull Exp Biol Med.* 2015 Aug;159(4):576–81. <https://www.ncbi.nlm.nih.gov/pubmed/26395626>
28. Ruiz-López FJ, Blanquer M. Autologous bone marrow mononuclear cells as neuroprotective treatment of amyotrophic lateral sclerosis. *Neural Regen Res.* 2016 Apr;11(4):568–9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870910/>
29. Syková E, Rychmach P, Drahorádová I, Konrádová Š, Růžičková K, Voříšek I, et al. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial. *Cell Transplant.* 2017 Apr 13;26(4):647–58. <https://www.ncbi.nlm.nih.gov/pubmed/27938483>
30. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. *Ann Neurol.* 2014 Mar;75(3):363–73. doi: 10.1002/ana.24113. Epub 2014 Mar 7. PubMed PMID: 24510776; PubMed Central PMCID: PMC4005820. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005820/>
31. Chen L, Chen D, Xi H, Wang Q, Liu Y, Zhang F, Wang H, Ren Y, Xiao J, Wang Y, Huang H. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateralsclerosis patients: benefits from multiple transplants. *Cell Transplant.* 2012;21 Suppl 1:S65–77. doi: 10.3727/096368912X633789. PubMed PMID: 22507682.

32. Mazzini L, Gelati M, Profico DC, Sorarù G, Ferrari D, Copetti M, Muzi G, Ricciolini C, Carletti S, Giorgi C, Spera C, Frondizi D, Masiero S, Stecco A, Cisari C, Bersano E, De Marchi F, Sarnelli MF, Querin G, Cantello R, Petruzzelli F, Maglione A, Zalfa C, Binda E, Visioli A, Trombetta D, Torres B, Bernardini L, Gaiani A, Massara M, Paolucci S, Boulis NM, Vescovi AL; ALS-NSCs Trial Study Group. Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome. *Stem Cells Transl Med.* 2019 Sep;8(9):887-897. doi: 10.1002/sctm.18-0154. Epub 2019 May 18. PmiD: 31104357; PMCID: PMC6708070.
33. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis. *Arch Neurol.* 2010 Oct;67(10):1187–94. <https://www.ncbi.nlm.nih.gov/pubmed/20937945>
34. Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. *Front Biosci (Landmark Ed).* 2021 Oct 30;26(10):693-706. doi: 10.52586/4980. PmiD: 34719198.
35. Siwek T, Jezierska-Woźniak K, Maksymowicz S, Barczewska M, Sowa M, Badowska W, Maksymowicz W. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis. *Med Sci Monit.* 2020 Dec 10;26:e927484. doi: 10.12659/MSM.927484. PmiD: 33301428; PMCID: PMC7737405.
36. Tavakol-Afshari J, Boroumand AR, Farkhad NK, Moghadam AA, Sahab-Negah S, Gorji A. Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis. *Regenerative Therapy.* 2021 Dec 1;18:268-74.
37. Martínez HR, Molina-Lopez JF, González-Garza MT, et al. Stem Cell Transplantation in Amyotrophic Lateral Sclerosis Patients: Methodological Approach, Safety, and Feasibility. *Cell Transplantation.* 2012;21(9):1899-1907. doi:10.3727/096368911X582769
38. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. *Neurology [Internet].* 2008 Oct 20 [cited 2022 Sep 22];71(17):1326-34. Available from: <https://doi.org/10.1212/01.wnl.0000327668.43541.22>

39. Sharma A., Sane H., Paranjape A., Varghese R., Nair V., Biju H., Sawant D., Gokulchandran N., Badhe P. Improved survival in Amyotrophic Lateral Sclerosis patients following Autologous Bone Marrow Mononuclear Cell Therapy: A Long term 10-year retrospective study, Journal of Neurorestoratology, 2021, 9(2): 117–136
40. Shigematsu K, Takeda T, Komori N, Urushihata N, Oki K, Tahara K, Yamagishi H. Long-term survival of a patient with amyotrophic lateral sclerosis (ALS) who received autologous adipose-derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci. 2021 Jun 1;25(11):4086-90.
41. Hassan AA, Elkins J, Hassan HY. Case Report: Stem cell therapy in amyotrophic lateral sclerosis. F1000Res. 2021 Oct 25;10:1080. doi: 10.12688/f1000research.73967.2. PMID: 35087666; PMCID: PMC8762680.
42. "minguell J. J. ,Allers C. , Jones J. A. , Ganji S. S.Allogeneic Mesenchymal Stem Cells Infusion to an ALS Patient Proved to be Safe and Capable to Initiate Clinical RecuperationCellR4 2013; 1 (3): e530"
43. Brennan S, Keon M, Su Z, Liu B, Song XM, Zaw T, McKay M, Pascovici D, Saksena NK. Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS. OBM Geriatrics 2021; 5(1): 164; doi:10.21926/obm.geriatr.2101164.
44. Uriel Ayllón Álvarez D, Neri Calixto M, Humberto Aparicio Albarrán C, Mendieta Zerón H. AUTOLOGOUS STEM CELL TRANSPLANTATION AND IMMUNOMODULATION IN AMYOTROPHIC LATERAL SCLEOROSIS. MNJ (Malang Neurology Journal) [Internet]. 2021 Jul 1 [cited 2022 Sep 22];7(2):140-5. Available from: <https://doi.org/10.21776/ub.mnj.2021.007.02.12>
45. Sharma A, Sane H, Paranjape A, Pradhan R, Das R, Biju H, Gokulchandran N, Badhe P. Multiple doses of cell therapy and neurorehabilitation in amyotrophic lateral sclerosis: A case report. Clin Pract. 2020 Sep 28;10(3):1242. doi: 10.4081/cp.2020.1242. PMID: 33072247; PMCID: PMC7533601.
46. Sharma, A., Sane, H., Pradhan, R., Paranjape, A., Gokulchandran, N., Kaur, J., Das, R., & Badhe, P. (2019). Neuroregenerative Rehabilitation Therapy with long-term Lithium in a Male Amyotrophic Lateral Sclerosis Patient: A Case Report. International Journal of Medical Science and Clinical Invention, 2019, 6(2): 4337-4344. <https://doi.org/10.18535/ijmisci/v6i2.11>

47. Alok Sharma, Hemangi Sane, Sarita Kaliburgi, Amruta Paranjape, Nandini Gokulchandran, Prerna Badhe, "Potential Benefits of Cellular Transplantation in a Patient with Amyotrophic Lateral Sclerosis". Current Opinions in Neurological Science 1.2 (2017): 31-43
48. Sharma A, Sane H, Sawant D, Paranjape A, Inamdar S, Kaur J, Gokulchandran N, Badhe P. Cellular Therapy in Amyotrophic Lateral Sclerosis: A Case Report; International Journal of Recent Advances in Multidisciplinary Research. 2017;1(4):2605-2609
49. Hemangi Sane, Alok Sharma, Nandini Gokulchandran, Sarita Kaliburgi, Amruta Paranjape, Prerna Badhe. Neurorestoration in Amyotrophic Lateral Sclerosis - A case report. Indian Journal of Stem Cell therapy. 2016; 2(1):29-37
50. Alok Sharma, Prerna Badhe, Omshree Shetty, Pooja Vijaygopal, Nandini Gokulchandran, V.C. Jacob, Mamta Lohia, Hema Biju, Guneet Chopra. Autologous bone marrow derived stem cells for motor neuron disease with anterior horn cell involvement. Bombay hospital journal. 2011; 53(1): 71- 75.

Muscular dystrophy

1. Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marbán L, Ascheim DD, Marbán E, Victor RG. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. *Neurology*. 2019 Feb 19;92(8):e866-e878. doi: 10.1212/WNL.0000000000006950. Epub 2019 Jan 23. PMID: 30674601; PMCID: PMC6396968.
2. Rajput BS, Chakrabarti SK, Dongare VS, Ramirez CM, Deb KD. Human umbilical cord mesenchymal stem cells in the treatment of Duchenne muscular dystrophy: safety and feasibility study in India. *Journal of stem cells*. 2015 Apr 1;10(2):141. <https://www.ncbi.nlm.nih.gov/pubmed/27125141>
3. Li P, Cui K, Zhang B, Wang Z, Shen Y, Wang X, Zhang J, Tong F, Li S. Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members. *International journal of molecular medicine*. 2015 Apr 1;35(4):1051-7. <https://www.ncbi.nlm.nih.gov/pubmed/25647308>
4. Cossu G, Previtali SC, Napolitano S, Cicalese MP, Tedesco FS, Nicastro F, Noviello M, Roostalu U, Sora MG, Scarlato M, De Pellegrin M. Intra-arterial transplantation of HLA-matched donor

- mesoangioblasts in Duchenne muscular dystrophy. *EMBO molecular medicine*. 2015 Dec 1;7(12):1513-28. <https://www.ncbi.nlm.nih.gov/pubmed/26543057>
5. Sharma A, Sane H, Badhe P, Gokulchandran N, Kulkarni P, Lohiya M, Biju H, Jacob VC. A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. *Cell transplantation*. 2013 Jan;22(1_suppl):127-38. <https://www.ncbi.nlm.nih.gov/pubmed/24070109>
 6. Skuk D, Roy B, Goulet M, Chapdelaine P, Bouchard JP, Roy R, Dugré FJ, Lachance JG, Deschênes L, Senay H, Sylvain M. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. *Molecular Therapy*. 2004 Mar 1;9(3):475-82. <https://www.ncbi.nlm.nih.gov/pubmed/15038390>
 7. Torrente Y, Belicchi M, Marchesi C, D'antona G, Cogiamanian F, Pisati F, Gavina M, Giordano R, Tonlorenzi R, Fagiolari G, Lamperti C. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. *Cell transplantation*. 2007 Jul;16(6):563-77. <https://www.ncbi.nlm.nih.gov/pubmed/17912948>
 8. Yang XF, Xu YF, Zhang YB, Wang HM, Lü NW, Wu YX, Lü X, Cui JP, Shan H, Yan Y, Zhou JX. Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem cell transplantations. *Zhonghuayixue za zhi*. 2009 Sep;89(36):2552-6. <https://www.ncbi.nlm.nih.gov/pubmed/20137617>
 9. Law PK, Goodwin TG, Fang Q, Chen M, Li HJ, Floredo JA, Dana S, Kirby BS. Myoblast transfer therapy for Duchenne muscular dystrophy. *Pediatrics International*. 1991 Apr;33(2):206-15. <https://www.ncbi.nlm.nih.gov/pubmed/1957647>
 10. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, Richards CL. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. *Cell transplantation*. 1993 Mar;2(2):99-112. <https://www.ncbi.nlm.nih.gov/pubmed/8143083>
 11. Périé S, Trollet C, Mouly V, Vanneaux V, Mamchaoui K, Bouazza B, Marolleau JP, Laforêt P, Chapon F, Eymard B, Butler-Browne G. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. *Molecular Therapy*. 2014 Jan 1;22(1):219-25. <https://www.ncbi.nlm.nih.gov/pubmed/23831596>
 12. Klimczak A, Zimna A, Malcher A, Kozlowska U, Futoma K, Czarnota J, Kemnitz P, Bryl A, Kurpisz M. Co-Transplantation of Bone Marrow-MSCs and Myogenic Stem/Progenitor Cells

- from Adult Donors Improves Muscle Function of Patients with Duchenne Muscular Dystrophy. Cells. 2020 Apr 30;9(5):1119. doi: 10.3390/cells9051119. PmiD: 32365922; PMCID: PMC7290387.
13. Duzhar VM, Radchenko VV, Gozhenko AI, Badiuk NS. DUCHENNE MUSCULAR DYSTROPHY: TREATMENT WITH FETAL PROGENITOR CELL TRANSPLANT.
 14. Shroff G.. Human Embryonic Stem Cells in the Treatment of Patients With Duchenne Muscular Dystrophy: A Case Series. Journal of Neurology Research, North America, 5, apr. 2015.
 15. Sharma A, Sane H, Gokulchandran N, Gandhi S, Bhovad P, Khopkar D, Paranjape A, Bhagwanani K, Badhe P. The role of cell therapy in modifying the course of limb girdle muscular dystrophy- A Longitudinal 5-year study. Degenerative Neurological and Neuromuscular Disease 2015;5 93–102
 16. "Dai A, Baspinar O, Yeşilyurt A, Sun E, Aydemir ÇI, Öztel ON, Capkan DU, Pinarli F, Agar A, KaraözE. Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchennemuscular dystrophy - Phase I-II. Degener Neurol Neuromuscul Dis. 2018 Oct 26;8:63-77."
 17. Zhang C, Feng HY, Huang SL, Fang JP, Xiao LL, Yao XL, Chen C, Ye X, Zeng Y, Lu XL, Wen JM, Zhang WX, Li Z, Feng SW, Xu HG, Huang K, Zhou DH, Chen W, Xie YM, Xi J, Zhang M, Li Y, Liu Y. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Aug;22(4):399-405. Chinese. PmiD: 16086277.
 18. Sinha, Rupam1; Sarkar, Soumyabrata1; Khaitan, Tanya1,; Dutta, Soumyajit1. Duchenne muscular dystrophy: Case report and review. Journal of Family Medicine and Primary Care: Jul–Sep 2017 - Volume 6 - Issue 3 - p 654-656 doi: 10.4103/2249-4863.222015
 19. Sharma A, Kulkarni P, Chopra G, Gokulchandran N, Lohia M, Badhe P. Autologous Bone Marrow Derived Mononuclear Cell Transplantation In Duchenne Muscular Dystrophy-A Case Report. Indian journal of Clinical Practice. 2012; 23 (3): 169-72.
 20. Sharma A, Paranjape A, Sane H, Bhagawanani K, Gokulchandran N, Badhe P. Cellular transplantation alters the disease progression in Becker's muscular dystrophy. Case reports in transplantation. 2013;2013.: 909328.

21. Sharma A., Sane, H., Paranjape, A., Badhe, P., Gokulchandran, N., & Jacob, V. Effect of Cellular Therapy seen on Musculoskeletal Magnetic Resonance Imaging in a Case of Becker's Muscular Dystrophy. *Journal of Case Reports*. 2013; 3(2): 440-447.
22. Sharma A, Sane H, Gokulchandran N, Sharan, R., Paranjape, A., Kulkarni, P., Yadav J, Badhe, P. Effect of Cellular Therapy in Progression of Becker's Muscular Dystrophy: A Case Study. *European Journal of Translational Myology*. 2016;26(1):5522.
23. Sharma A, Sane H, Kaur J, Gokulchandran N, Paranjape A, Yadav J, Badhe P. Autologous bone marrow mononuclear cell transplantation improves function in a case of Becker's muscular dystrophy. *American Based Research Journal*. 2016;5(2):1-2.
24. Sharma A , Badhe P, Sane H, Pai S, Kulkarni P, Bhagwanani K, Gokulchandran N. Halting of functional decline in a case of Duchenne Muscular Dystrophy after cellular therapy. *International Journal of Recent Advances in Multidisciplinary Research (IJRAMR)*,2017;04(02), pp.2293-2297
25. Sharma A, Sane H, Paranjape A, Bhagwanani K, Gokulchandran N, Badhe P. Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy – a case report. *American journal of case reports*. 2014;15: 128-134.
26. Sharma A, Gokulchandran N, Sane H, Lakhanpal V, Kulkarni P, et al. Stabilization Of Disease Progression In A Case Of Duchenne Muscular Dystrophy With Cellular Transplantation. *Stem Cell Adv Res Ther*. 2017; 2017: J112. DOI: 10.29011/SCRT-112. 000012
27. Sharma A; Sane H; Varghese R; Paranjape A; Nivins S; Inamdar S; Gokulchandran N; Badhe P. Potential benefits of serial cell transplantation in a case of Duchenne Muscular Dystrophy. *Open Journal of Clinical and Medical Case Report*, 2018;4(4); 1382
28. Sharma A, Sane H, Kulkarni P, Mehta D, Kaur J, Gokulchandran N, Bhagwanani K, Badhe P. Effect Of Autologous Bone Marrow Mononuclear Cell Transplantation Coupled With Rehabilitation In Limb Girdle Muscular Dystrophy – A Case Report. *Int J Med Res Health Sci*. 2016, 5(12):1-7
29. Alok S, Amruta P, Ritu V, Hemangi S, Nandini G, et al. Functional Improvements and Musculoskeletal Magnetic Resonance Imaging with Spectroscopy Changes following Cell Therapy in a Case of Limb Girdle Muscular Dystrophy. *Int J cell Sci & mol biol*. 2017; 2(4) : 555595.

30. Sharma A, Paranjape A, Sane H, Gokulchandran N, Sawant D, Shirke S, Nair V, Inamdar S, Badhe P. Effect of Cellular Therapy in a case of Limb Girdle Muscular Dystrophy. International Journal Of Current Medical And Pharmaceutical Research, 2017; 3(09):pp.2377-2381
31. Kang PB, Lidov HG, White AJ, mitchell M, Balasubramanian A, Estrella E, Bennett RR, Darras BT, Shapiro FD, Bambach BJ, Kurtzberg J, Gussoni E, Kunkel LM. Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. Muscle Nerve. 2010 Jun;41(6):746-50."
32. McDonald CM, Marbán E, Hendrix S, Hogan N, Smith RR, Eagle M, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2022;399(10329):1049-1058."